PCSK9 and familial hypercholesterolemia: Gain of function mutations in PCSK9 results in reduced LDLr levels and subsequently hypercholesterolemia [194], while loss of function mutations increase LDLr levels, thereby lowering circulating LDL cholesterol and providing protection from coronary artery disease.